Natixis Edgewise Therapeutics, Inc. Transaction History
Natixis
- $17.6 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding EWTX
# of Institutions
192Shares Held
100MCall Options Held
2.17MPut Options Held
410K-
Orbimed Advisors LLC San Diego, CA15MShares$443 Million9.45% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.91MShares$263 Million3.32% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$177 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY5.84MShares$172 Million1.67% of portfolio
-
Novo Holdings Hellerup, G75.55MShares$164 Million10.36% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $1.86B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...